Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy

Texto completo
Autor(es):
Verza, Flavia Alves [1] ; Das, Umashankar [2] ; Fachin, Ana Lucia [1, 3] ; Dimmock, Jonathan R. [2] ; Marins, Mozart [1, 3, 2, 4]
Número total de Autores: 5
Afiliação do(s) autor(es):
[1] Univ Ribeirao Preto, Biotechnol Unit, BR-14096900 Ribeirao Preto, SP - Brazil
[2] Univ Saskatchewan, Coll Pharm & Nutr, 110 Sci Pl, Saskatoon, SK S7N 5C9 - Canada
[3] Univ Ribeirao Preto, Med Sch, BR-14096900 Ribeirao Preto, SP - Brazil
[4] Univ Ribeirao Preto, Pharmaceut Sci Sch, BR-14096900 Ribeirao Preto, SP - Brazil
Número total de Afiliações: 4
Tipo de documento: Artigo de Revisão
Fonte: CANCERS; v. 12, n. 6 JUN 2020.
Citações Web of Science: 0
Resumo

Histones are the main structural proteins of eukaryotic chromatin. Histone acetylation/ deacetylation are the epigenetic mechanisms of the regulation of gene expression and are catalyzed by histone acetyltransferases (HAT) and histone deacetylases (HDAC). These epigenetic alterations of DNA structure influence the action of transcription factors which can induce or repress gene transcription. The HATs catalyze acetylation and the events related to gene transcription and are also responsible for transporting newly synthesized histones from the cytoplasm to the nucleus. The activity of HDACs is mainly involved in silencing gene expression and according to their specialized functions are divided into classes I, II, III and IV. The disturbance of the expression and mutations of HDAC genes causes the aberrant transcription of key genes regulating important cancer pathways such as cell proliferation, cell-cycle regulation and apoptosis. In view of their role in cancer pathways, HDACs are considered promising therapeutic targets and the development of HDAC inhibitors is a hot topic in the search for new anticancer drugs. The present review will focus on HDACs I, II and IV, the best known inhibitors and potential alternative inhibitors derived from natural and synthetic products which can be used to influence HDAC activity and the development of new cancer therapies. (AU)

Processo FAPESP: 18/50008-1 - Synthesis and discovery of molecular mechanisms of some novel conjugated unsaturated ketones designed as anticancer agents
Beneficiário:Mozart de Azevedo Marins
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 19/03074-1 - Explorando a atividade do fator de transcrição Sp1 associada a transição epitélio mesenquimal como alvo terapêutico do osteossarcoma
Beneficiário:Mozart de Azevedo Marins
Linha de fomento: Auxílio à Pesquisa - Regular